Table 1.
Patient and graft characteristics
| Characteristic | No. patients | % |
|---|---|---|
| Sex | ||
| Female | 39 | 43.8 |
| Male | 50 | 56.2 |
| Race | ||
| Caucasian | 67 | 75.3 |
| African American | 6 | 6.7 |
| Other | 16 | 18 |
| Primary diagnosis | ||
| AML | 31 | 34.8 |
| ALL | 28 | 31.5 |
| CML | 21 | 23.6 |
| MDS | 9 | 10.1 |
| Disease status at allo-HSCT | ||
| Standard-risk | 59 | 66.3 |
| High-risk | 30 | 33.7 |
| Donor | ||
| Unrelated | 41 | 46.1 |
| Matched sibling | 37 | 41.6 |
| Parent | 11 | 12.3 |
| HSC product | ||
| Bone marrow | 79 | 88.8 |
| Blood stem cell | 10 | 11.2 |
| HLA match | ||
| 6/6 | 70 | 78.6 |
| 5/6 | 8 | 9 |
| 4/6 | 2 | 2.3 |
| 3/6 | 9 | 10.1 |
| T cell–depleted graft | ||
| Yes | 41 | 46.1 |
| No | 48 | 53.9 |
| Cytomegalovirus status (recipient/donor) | ||
| −/− | 27 | 30.3 |
| +/− | 12 | 13.5 |
| −/+ | 15 | 16.9 |
| +/+ | 35 | 39.3 |
| Conditioning chemotherapy | ||
| Cyclophosphamide + cytarabine | 55 | 61.8 |
| Cyclophosphamide + thiotepa | 22 | 24.7 |
| Cyclophosphamide | 8 | 9 |
| Other | 4 | 4.5 |
| TBI dose | ||
| 0 Gy | 3 | 3.4 |
| 12 Gy | 55 | 61.8 |
| 14 Gy | 31 | 34.8 |
| Use of ATG, OKT-3, or alemtuzumab | ||
| Yes | 49 | 55.1 |
| No | 40 | 44.9 |
| Acute GVHD | ||
| none | 45 | 50.6 |
| Grade I–II | 40 | 44.9 |
| Grade III–IV | 4 | 4.5 |
| Chronic GVHD | ||
| None | 66 | 74.2 |
| Limited | 17 | 19.1 |
| Extensive | 6 | 6.7 |
| Respiratory problems | ||
| Within 1 year post–allo-HSCT | 14 | 15.7 |
| More than 1 year post–allo-HSCT | 7 | 7.9 |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; CML, chronic myeloid leukemia; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; MDS, myelodysplastic syndrome; No., number; TBI, total body irradiation